[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20130324A1 - Proteinas de fusion que comprenden un antigeno prame (dage) - Google Patents

Proteinas de fusion que comprenden un antigeno prame (dage)

Info

Publication number
PE20130324A1
PE20130324A1 PE2012001372A PE2012001372A PE20130324A1 PE 20130324 A1 PE20130324 A1 PE 20130324A1 PE 2012001372 A PE2012001372 A PE 2012001372A PE 2012001372 A PE2012001372 A PE 2012001372A PE 20130324 A1 PE20130324 A1 PE 20130324A1
Authority
PE
Peru
Prior art keywords
fusion protein
amino acids
protein
dage
fusion proteins
Prior art date
Application number
PE2012001372A
Other languages
English (en)
Inventor
Normand Blaise
Denis Martin
Remi M Palmantier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39300029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0700760A external-priority patent/GB0700760D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20130324A1 publication Critical patent/PE20130324A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189PRAME
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE: (a) UN PRAME O UN FRAGMENTO INMUNOLOGICO DEL MISMO QUE CONSTA DE UNO O MAS DE LOS EPITOPES SIGUIENTES: (i) VLDGLDVLL; (ii) SLYSFPEPEA ; ENTRE OTROS; (b) UNA PROTEINA PAREJA DE FUSION HETEROLOGA DERIVADA DE PROTEINA D QUE ESTA CONSTITUIDA POR LOS AMINOACIDOS 20 A 127 DE LA PROTEINA D Y LOS AMINOACIDOS LYS-21 Y LEU-22 ESTAN SUSTITUIDOS CON LOS AMINOACIDOS ASP-21 Y PRO-22; (C) UNA O MAS SECUENCIAS DE ENGARCE ENTRE LA PROTEINA FUSION Y EL ANTIGENO TUMORAL. REFERIDA ADEMAS A UN PROCEDIMIENTO Y A UNA VACUNA QUE CONTIENE UN COADYUVANTE TALES COMO 3D-MPL, QS21 Y/O OLIGONUCLEOTIDO CpG, Y/O UNA CITOQUINA O QUIMIOQUINA INMUNOESTIMULADORA. DICHA COMPOSICION QUE CONTIENE LA PROTEINA DE FUSION ES UTIL EN EL TRATAMIENTO DEL CANCER.
PE2012001372A 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage) PE20130324A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0700760A GB0700760D0 (en) 2007-01-15 2007-01-15 Vaccine
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine

Publications (1)

Publication Number Publication Date
PE20130324A1 true PE20130324A1 (es) 2013-03-05

Family

ID=39300029

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000124A PE20081686A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)
PE2012001372A PE20130324A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008000124A PE20081686A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)

Country Status (32)

Country Link
US (1) US20080187535A1 (es)
EP (1) EP2114993B1 (es)
JP (1) JP5391080B2 (es)
KR (1) KR20090101313A (es)
CN (1) CN101668770B (es)
AR (1) AR064862A1 (es)
AU (1) AU2008207025B2 (es)
BR (1) BRPI0806463A2 (es)
CA (1) CA2674552A1 (es)
CL (1) CL2008000104A1 (es)
CO (1) CO6210757A2 (es)
CR (1) CR10971A (es)
CY (1) CY1113760T1 (es)
DK (1) DK2114993T3 (es)
DO (1) DOP2009000167A (es)
EA (1) EA016326B1 (es)
ES (1) ES2393812T3 (es)
HK (1) HK1138853A1 (es)
HR (1) HRP20120828T1 (es)
IL (1) IL199663A0 (es)
JO (1) JO2840B1 (es)
MA (1) MA31093B1 (es)
MX (1) MX2009007571A (es)
MY (1) MY153679A (es)
NZ (1) NZ578285A (es)
PE (2) PE20081686A1 (es)
PL (1) PL2114993T3 (es)
PT (1) PT2114993E (es)
SI (1) SI2114993T1 (es)
TW (1) TWI434697B (es)
WO (1) WO2008087102A1 (es)
ZA (1) ZA200904923B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2118128B1 (en) * 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
JP2012520663A (ja) 2009-03-17 2012-09-10 エムディーエックスヘルス エスエー 遺伝子発現の改良された検出
EP2438173A4 (en) * 2009-06-05 2012-10-31 Univ Ohio State Res Found BIOMATERIALS, COMPOSITIONS AND METHODS
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
KR20140049569A (ko) 2011-07-22 2014-04-25 글락소스미스클라인 바이오로지칼즈 에스.에이. Prame 정제
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2590701C2 (ru) * 2013-04-29 2016-07-10 Общество с ограниченной ответственностью "ГеноТехнология" Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
US20160367651A1 (en) 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
CN105254767A (zh) * 2015-11-17 2016-01-20 重庆科润生物医药研发有限公司 一种Protein D与HER2融合蛋白及其制备方法和应用
NZ753307A (en) 2016-11-30 2023-10-27 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别源自于prame抗原短肽的tcr
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别prame抗原短肽的tcr及其相关组合物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
US20210177955A1 (en) * 2017-11-08 2021-06-17 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术(广东)有限公司 针对prame的高亲和力t细胞受体
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
JP2024518378A (ja) 2021-05-05 2024-05-01 イマティクス バイオテクノロジーズ ゲーエムベーハー Prameに特異的に結合する抗原結合タンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2156718A1 (en) * 1993-12-23 1995-06-29 Bruno Gander Immunological response potentiation process
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
SI1659179T1 (sl) * 1998-02-05 2011-10-28 Glaxosmithkline Biolog Sa S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje
EP1156825A2 (en) * 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
WO2001000232A2 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
CN1367875A (zh) * 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法

Also Published As

Publication number Publication date
JO2840B1 (en) 2014-09-15
ES2393812T3 (es) 2012-12-28
ZA200904923B (en) 2012-12-27
WO2008087102A1 (en) 2008-07-24
EP2114993B1 (en) 2012-08-29
PE20081686A1 (es) 2008-12-25
HK1138853A1 (en) 2010-09-03
HRP20120828T1 (hr) 2012-11-30
NZ578285A (en) 2011-12-22
MY153679A (en) 2015-03-13
KR20090101313A (ko) 2009-09-24
IL199663A0 (en) 2010-04-15
PT2114993E (pt) 2012-11-28
EP2114993A1 (en) 2009-11-11
MA31093B1 (fr) 2010-01-04
US20080187535A1 (en) 2008-08-07
TWI434697B (zh) 2014-04-21
BRPI0806463A2 (pt) 2011-09-06
MX2009007571A (es) 2009-07-22
SI2114993T1 (sl) 2012-12-31
PL2114993T3 (pl) 2013-01-31
CY1113760T1 (el) 2016-07-27
AU2008207025A1 (en) 2008-07-24
AR064862A1 (es) 2009-04-29
DK2114993T3 (da) 2012-10-22
CN101668770B (zh) 2013-06-12
CR10971A (es) 2009-09-09
TW200902048A (en) 2009-01-16
EA016326B1 (ru) 2012-04-30
CN101668770A (zh) 2010-03-10
JP5391080B2 (ja) 2014-01-15
EA200900795A1 (ru) 2010-02-26
CO6210757A2 (es) 2010-10-20
JP2010515444A (ja) 2010-05-13
CL2008000104A1 (es) 2008-07-18
AU2008207025B2 (en) 2012-08-23
CA2674552A1 (en) 2008-07-24
DOP2009000167A (es) 2009-07-15

Similar Documents

Publication Publication Date Title
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CL2024000411A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
DOP2020000032A (es) Proteínas de unión específicas y sus usos
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
PE20150605A1 (es) Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
CL2016001405A1 (es) A peptide mixture
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
ES2337399T3 (es) Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18
UY32915A (es) Proteínas de únión específicas y sus usos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
PE20081687A1 (es) Proteina de fusion

Legal Events

Date Code Title Description
FC Refusal